Anders A. Jensen

Anders A. Jensen

Auto-generated profile, based on publicly available information

Anders A. Jensen

University of Copenhagen

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AJAnders A. Jensen
Anders A. Jensen
BFBente Frølund
Bente Frølund
TLTommy Liljefors
Tommy Liljefors
PKPovl Krogsgaard-Larsen
Povl Krogsgaard-Larsen

1 February 2018 in Cell
Verified
Journal Article
Closed access
YPYao Peng
Yao Peng
JMJohn D. McCorvy
John D. McCorvy
KHKasper Harpsøe
Kasper Harpsøe
KLKatherine Lansu
Katherine Lansu
SYShuguang Yuan
Shuguang Yuan
ZLZhi-Jie Liu
Zhi-Jie Liu

1 January 2007 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
HBHans Bräuner-Osborne
Hans Bräuner-Osborne
PWPetrine Wellendorph
Petrine Wellendorph
AJAnders A. Jensen
Anders A. Jensen
Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu1-8) receptors, two heterodimeric -aminobutyric acidB (GABAB) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L- α-amino acid receptor (GPRC6A), and five orphan receptors. Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists. Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported. Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets. So far, two drugs acting at family C receptors (the GABAB agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed. Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class. In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.

31 October 2018 in Nature
Verified
Journal Article
Closed access
PDF file
LPLucie Polovinkin
Lucie Polovinkin
GHGhérIci Hassaine
GhérIci Hassaine
JPJonathan Perot
Jonathan Perot
ENEmmanuelle Neumann
Emmanuelle Neumann
AJAnders A. Jensen
Anders A. Jensen
HNHugues Nury
Hugues Nury

1 June 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HBHans Bräuner-Osborne
Hans Bräuner-Osborne
AJAnders A. Jensen
Anders A. Jensen
PSPaul O. Sheppard
Paul O. Sheppard
POPatrick O'HAra
Patrick O'HAra
PKPovl Krogsgaard-Larsen
Povl Krogsgaard-Larsen
The calcium-sensing receptor (CaR) is a G-protein-coupled receptor that displays 19–25% sequence identity to the γ-aminobutyric acid type B (GABAB) and metabotropic glutamate (mGlu) receptors. All three groups of receptors have a large amino-terminal domain (ATD), which for the mGlu receptors has been shown to bind the endogenous agonist. To investigate whether the agonist-binding domain of the CaR also is located in the ATD, we constructed a chimeric receptor named Ca/1a consisting of the ATD of CaR and the seven transmembrane region and C terminus of mGlu1a. The Ca/1a receptor stimulated inositol phosphate production when exposed to the cationic agonists Ca2+, Mg2+, and Ba2+ in transiently transfected tsA cells (a transformed HEK 293 cell line). The pharmacological profile of Ca/1a (EC50 values of 3.3, 2.6, and 3.9 mm for these cations, respectively) was very similar to that of the wild-type CaR (EC50 values of 3.2, 4.7, and 4.1 mm, respectively). For the mGlu1a receptor, it has been shown that Ser-165 and Thr-188, which are located in the ATD, are involved in the agonist binding. An alignment of CaR with the mGlu receptors showed that these two amino acid residues have been conserved in CaR as Ser-147 and Ser-170, respectively. Each of these residues was mutated to alanines and tested pharmacologically using the endogenous agonist Ca2+. CaR-S147A showed an impaired function as compared with wild-type CaR both with respect to potency of Ca2+(4-fold increase in EC50) and maximal response (79% of wild-type response). CaR-S170A showed no significant response to Ca2+ even at 50 mm concentration. In contrast, each of the two adjacent mutations, S169A and S171A, resulted in pharmacological profiles almost identical to that of the wild-type receptor. These data demonstrate that Ser-170 and to some extent Ser-147 are involved in the Ca2+ activation of the CaR, and taken together, our results reveal a close resemblance of the activation mechanism between the CaR and the mGlu receptors.

21 September 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MEMette N. Erichsen
Mette N. Erichsen
THTri H. V. Huynh
Tri H. V. Huynh
Bjarke AbrahamsenBjarke Abrahamsen
Bjarke Abrahamsen
JBJesper F. Bastlund
Jesper F. Bastlund
CBChristoffer Bundgaard
Christoffer Bundgaard
LBLennart Bunch
Lennart Bunch